SANTA ROSA — Abdominal-stent maker TriVascular Technologies, Inc. (Nasdaq: TRIV), today announced the pricing of its initial public offering of 6.5 million shares of common stock at $12 per share, below its initial pricing of $13 to $15 per share.
The company’s shares are expected to begin trading on The NASDAQ Global Select Market on Wednesday under the ticker symbol “TRIV.” The offering is expected to close on April 22 subject to customary closing conditions. Santa Rosa-based Trivascular is seeking up to $89.7 million total from its IPO, down from $100 million originally stated in its IPO filing. Funds would go toward expanded marketing of its abdominal stent graft system as well as paying off a loan from Boston Scientific, which at one point owned TriVascular, according to a prospectus filed with the U.S. Securities & Exchange Commission.
If successful, TriVascular would be the third North Bay company to go public this year, following Novato-based rare-disorder drug developer Ultragenyx Pharmaceutical on Jan. 31 and Santa Rosa-based pharmaceutical developer Ruthigen on March 24.
In addition, TriVascular has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the same price.
J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated are acting as co-managers.
Copyright © 1988–2014 North Bay Business Journal
View the policy for linking to website content.